Welcome to our dedicated page for Apyx Medical Corporation news (Ticker: APYX), a resource for investors and traders seeking the latest updates and insights on Apyx Medical Corporation stock.
Apyx Medical Corporation (APYX) delivers innovative plasma-based energy systems for surgical and cosmetic applications. This news hub provides investors and medical professionals with timely updates on regulatory developments, product innovations, and strategic partnerships driving advancements in electrosurgical technology.
Access authoritative reporting on APYX's Advanced Energy segment developments, including Renuvion® system enhancements, and OEM manufacturing collaborations. Track financial performance updates, clinical study results, and market expansion initiatives critical to evaluating the company's position in medical device innovation.
Our curated news collection features earnings announcements, FDA clearances, research publications, and executive leadership changes. Stay informed about helium plasma technology applications in dermatology and general surgery through verified sources, maintained for accuracy and relevance.
Bookmark this page for streamlined access to APYX's evolving corporate narrative. Combine real-time updates with historical context to better understand this pioneer in energy-based surgical solutions.
Apyx Medical (NASDAQ: APYX) has launched the 'Renewing Lives' campaign, a nationwide initiative offering Renuvion treatments to individuals who would benefit from this advanced medical technology but may not have access to it. Renuvion is unique as the only FDA-cleared device for contracting subcutaneous tissue, targeting loose skin to improve physical appearance and potentially mental health.
Through this campaign, for every Renuvion procedure performed in the U.S., Apyx Medical will make donations to fund treatments for those in need. This program aims to enhance confidence and overall well-being. Interested individuals can submit their personal stories to potentially receive treatment and be featured in Apyx Medical's 'Real Patients. Real Results' campaign. For more information and to participate, visit www.Renuvion.com/RenewingLives.
Apyx Medical reported their first-quarter 2024 financial results with total revenue of $10.2 million, a 16% decrease year-over-year. The company reaffirmed its full-year 2024 financial outlook. The Advanced Energy segment revenue decreased by 23% while OEM segment revenue increased by 14%. Net loss attributable to stockholders increased by 118% year-over-year. The company announced various developments post quarter-end, including new data and treatment insights showcased at the Renuvion Users' Summit. Management reaffirmed the 2024 financial guidance, focusing on leveraging new clinical indications and products to drive market awareness.
Apyx Medical announced the retirement of Andrew Makrides as Chairman of the Board, who served the company since 1982, and the appointment of Stavros Vizirgianakis as the new Chairman. Makrides contributed to the company's growth over the years, while Vizirgianakis brings extensive medical device industry experience to the role.
FAQ
What is the current stock price of Apyx Medical Corporation (APYX)?
What is the market cap of Apyx Medical Corporation (APYX)?
